Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 5;13(3):463.
doi: 10.3390/genes13030463.

A Clinical Investigation on the Theragnostic Effect of MicroRNA Biomarkers for Survival Outcome in Cervical Cancer: A PRISMA-P Compliant Protocol for Systematic Review and Comprehensive Meta-Analysis

Peter Shaw  1   2 , Raghul Senthilnathan  3 , Srivarshini Sankar  3 , Ilamathi Ilangovan  3 , Gothandam Kodiveri Muthukaliannan  3 , Siddhartha Baxi  4 , Ravishankar Ram Mani  5 , Mogana Rajagopal  5 , Sasikala Chinnappan  5 , Ashok Kumar Balaraman  5 , Deepa Suresh  6 , Sunil Krishnan  7 , Madanmohan Gupta  8 , Thangavel Muthusamy  9 , Chitraabaanu Paranjothy  10 , Rama Jayaraj  11
Affiliations

A Clinical Investigation on the Theragnostic Effect of MicroRNA Biomarkers for Survival Outcome in Cervical Cancer: A PRISMA-P Compliant Protocol for Systematic Review and Comprehensive Meta-Analysis

Peter Shaw et al. Genes (Basel). .

Abstract

Background: The most often diagnosed malignancy in women worldwide is cancer of the cervix. It is also the most prevalent kind of gynecological cancer in women. This cancer originates in the opening of the cervix and spreads through sexual contact. Even though human papillomavirus (HPV) may not cause cancer immediately, it does develop over time as a result of the virus's lengthy persistence to cause dysplastic changes overtime, particularly in high-risk kinds. The primary objective of this research is to see if miRNAs are dysregulated as a result of treatment resistance in cervical cancer (CC). The aim is to see if these microRNAs may be utilized as biomarkers for detecting chemoresistance in CC, particularly for clinical applications.

Methods: The recommended protocol for comprehensive study and meta-analysis (PRISMA-P) standards will be utilized for the analysis and data interpretation. The bibliographic databases will be methodically searched using a combination of search keywords. Based on established inclusion and exclusion criteria, the acquired findings will be reviewed, and data retrieved from the selected scientific papers for systematic review. We will then construct a forest from the pooled Hazard ratio (HR) and 95% C.I. values, data obtained using the random-effects model.

Discussion: The focus of this study is to identify the function of miRNAs as a chemoresistance regulator and determine if they have the potential scope to be considered as biomarkers for cervical cancer. Through this systematic review and meta-analysis, the goal is to collect, compare, and analyze the data pertaining to the role of miRNAs in cervical cancer, thereby, enabling us to understand the role they play in chemosensitivity.

Keywords: biomarkers; cervical cancer; chemoresistance; miRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests.

Figures

Figure 1
Figure 1
Flow chart: its role has garnered massive attention from researchers who are trying to identify their roles in CC. One of the major tasks carried out by scientists is to identify how well miRNAs regulate chemoresistance in CC. Through this study, we are trying to correlate all the data and increase the understanding of the function of miRNAs in CC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hausen H.Z. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 1989;49:4677–4681. - PubMed
    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer Incidence and Mortality Worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Tian T., Gong X., Gao X., Li Y., Ju W., Ai Y. Comparison of survival outcomes of locally advanced cervical cancer by histopathological types in the surveillance, epidemiology, and end results (SEER) database: A propensity score matching study. Infect. Agents Cancer. 2020;15:33. doi: 10.1186/s13027-020-00299-3. - DOI - PMC - PubMed
    1. Small W., Jr., Bacon M.A., Bajaj A., Chuang L.T., Fisher B.J., Harkenrider M.M., Jhingran A., Kitchener H.C., Mileshkin L.R., Viswanathan A.N.J.C. Cervical cancer: A global health crisis. Cancer. 2017;123:2404–2412. doi: 10.1002/cncr.30667. - DOI - PubMed
    1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999;189:12–19. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. - DOI - PubMed

Publication types